Vesicant characteristics of oxapliplatin following antecubital extravasation

J. G. Kennedy, J. P. Donahue, B. Hoang, P. J. Boland

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Oxaliplatin is a novel class of platinum chermotherapeutic agent used in refractory adenocarcinoma. It has previously been regarded as a non-vesicant, and as such was considered safe to administer through peripheral veins. This report documents severe muscle and subcutaneous reaction with a single dose of oxaliplatin at the site of extravasation in a patient aged 58 years. Conventional therapeutic modalities were employed to reduce the effect of the soft tissue infiltrate. Despite that, significant muscle necrosis and fibrosis occurred. Surgery was deferred secondary to patient choice, and eventual extensive physical therapy restored function to the elbow joint. This case shows that oxaliplatin may not be an appropriate cytotoxic agent to be administered through a peripheral line and consideration must be made for central access when this drug is used. In addition, when extravasation does occur, the current report indicates that non-surgical management can be successful.

Original languageEnglish (US)
Pages (from-to)237-239
Number of pages3
JournalClinical Oncology
Issue number5
StatePublished - Aug 2003
Externally publishedYes


  • Extravasation
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Vesicant characteristics of oxapliplatin following antecubital extravasation'. Together they form a unique fingerprint.

Cite this